VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VNRX VolitionRX

Closed 02-27 16:00:00 EST

0.2130

-0.0220

-9.36%

盘后0.2118

-0.0012-0.56%

19:46 EST

High0.2430	Low0.2120	Vol1.30M
Open0.2400	D1 Closing0.2350	Amplitude13.19%
Mkt Cap28.88M	Tradable Cap19.67M	Total Shares135.57M
T/O288.56K	T/O Rate1.41%	Tradable Shares92.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VNRX","market":"US","secType":"STK","nameCN":"VolitionRX","latestPrice":0.213,"timestamp":1772226000000,"preClose":0.235,"halted":0,"volume":1299511,"hourTrading":{"tag":"盘后","latestPrice":0.2118,"preClose":0.213,"latestTime":"19:46 EST","volume":23190,"amount":5010.38925,"timestamp":1772239581185,"change":-0.0012,"changeRate":-0.005634,"amplitude":0.039906},"delay":0,"changeRate":-0.09361702127659571,"floatShares":92348900,"shares":135565300,"eps":-0.22881,"marketStatus":"Closed","change":-0.022,"latestTime":"02-27 16:00:00 EST","open":0.24,"high":0.243,"low":0.212,"amount":288557.57411479,"amplitude":0.131915,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.22881,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1423198800000,"exchange":"AMEX","adjPreClose":0.235,"preHourTrading":{"tag":"盘前","latestPrice":0.2303,"preClose":0.235,"latestTime":"09:24 EST","volume":26415,"amount":6311.652929999999,"timestamp":1772202286566,"change":-0.0047,"changeRate":-0.02,"amplitude":0.072766},"postHourTrading":{"tag":"盘后","latestPrice":0.2118,"preClose":0.213,"latestTime":"19:46 EST","volume":23190,"amount":5010.38925,"timestamp":1772239581185,"change":-0.0012,"changeRate":-0.005634,"amplitude":0.039906},"volumeRatio":0.437772,"impliedVol":0.1508,"impliedVolPercentile":0.4502},"requestUrl":"/m/hq/s/VNRX/wiki","defaultTab":"wiki","newsList":[{"id":"2614408780","title":"VolitionRx reports progress on Capture-Seq, Nu.Q lung cancer reimbursement, and Nu.Q NETs sepsis program in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2614408780","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614408780?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:10","pubTimestamp":1772025018,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. reported recent clinical and commercial progress across its platforms. The company said a manuscript describing its Capture-Seq platform for cancer detection has been submitted for peer review and cited an estimated $23 billion annualized total addressable market. For lung cancer, Volition said reimbursement submission preparation in France is underway with support from Hospices Civils de Lyon, and it expects routine clinical use in France by Q4 2026; it also noted receiving its first order for Nu.Q Cancer assays for clinical certification in Q4 2025. In sepsis, Volition said its CE-marked Nu.Q NETs assay has been included in the government-backed DETECSEPS program in France, a program valued at approximately $7.3 million. In veterinary testing, Volition reported feline lymphoma study results showing 100% specificity and detection of over 80% of feline lymphomas, and said publication in a peer-reviewed journal is expected to unlock a $5 million contractual milestone pay","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL5wfys7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2613290005","title":"VolitionRX Issues Unregistered Shares to Lind Global Asset Management XII LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2613290005","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613290005?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:16","pubTimestamp":1771625771,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. reported unregistered issuances of common stock to Lind Global Asset Management XII LLC in connection with repayment obligations under a $7.5 million senior secured convertible promissory note. The company issued 1,893,936 shares on Jan. 16, 2026, 2,569,753 shares on Jan. 29, 2026, and 1,956,178 shares on Feb. 17, 2026, to satisfy scheduled payment amounts. VolitionRx also disclosed a separate September 2025 private placement to an existing stockholder of 483,870 shares and warrants for up to an additional 483,870 shares at $0.682 per share, for gross proceeds of $300,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL4xwx4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2610914628","title":"VolitionRX Appoints MBL as Distributor for Nu.Q Discover Assays in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610914628","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610914628?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:07","pubTimestamp":1770728835,"startTime":"0","endTime":"0","summary":"VolitionRx Limited has announced the appointment of Medical & Biological Laboratories Co. Ltd  as a non-exclusive distributor of its Nu.Q Discover assays in Japan. The company also reported the first agreement with a leading pharmaceutical company to utilize its Nu.Q Discover biomarkers in a longitudinal Phase 1/2b clinical study, marking the first in-human clinical use of these biomarkers. Additionally, VolitionRx highlighted the commercial sale of its High Throughput Synthetic Sepsis method, which measures Neutrophil Extracellular Traps  activation and inhibition in whole blood. Through its Nu.Q Discover platform, VolitionRx is now serving close to 100 clients worldwide, including pharmaceutical and diagnostic companies, some of which have advanced to late-stage clinical trials using VolitionRx assays as pharmacodynamic biomarkers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL6p24xP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2610266174","title":"VolitionRx Faces NYSE American Non-Compliance Notice Over Equity Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2610266174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610266174?lang=en_us&edition=fundamental","pubTime":"2026-02-10 06:20","pubTimestamp":1770675611,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. has received a notice from the NYSE American indicating that it is not in compliance with the exchange's continued listing standards due to insufficient stockholders' equity and reported losses over recent fiscal years. The company must submit a compliance plan by March 8, 2026, and regain compliance by August 6, 2027, or face potential delisting. The company's shares will continue trading with a \".BC\" designation to indicate their below compliance status. This regulatory issue does not currently affect the company's business operations or SEC reporting requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on February","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL2VXlxg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2610366123","title":"VolitionRX Receives Notice of Non-Compliance With Nyse American Continued Listing Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2610366123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610366123?lang=en_us&edition=fundamental","pubTime":"2026-02-10 06:20","pubTimestamp":1770675600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA6YHJRS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2608362002","title":"VolitionRx Unveils Clinical Study Showing Nu.Q NETs Blood Test Guides Hidradenitis Suppurativa Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362002","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608362002?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:45","pubTimestamp":1770212721,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. has announced the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation  Conference, where results from a recent clinical study will be presented. The session, led by Professor Evangelos J. Giamarellos-Bourboulis, will focus on the use of the Nu.Q NETs assay as a blood test for classifying Hidradenitis Suppurativa  patients and guiding treatment selection and modification. The study demonstrates that Nu.Q NETs can be used to support personalized treatment approaches for HS, a chronic disease affecting approximately 1% of the global population. The Nu.Q NETs assay is CE-Marked and available for clinical use in the European Union, European Economic Area countries, and the United Kingdom. Data from the study will be presented at the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL8nMd0K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2607514046","title":"VolitionRX Limited Announces the Preparation of Reimbursement Submission for Its Nu.q® Cancer Assays","url":"https://stock-news.laohu8.com/highlight/detail?id=2607514046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607514046?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:50","pubTimestamp":1769781000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA6QMCD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2607046984","title":"VolitionRX Ltd: Once Reimbursement Achieved Anticipate Introduction of Nu.q Into Routine Clinical Use in France by Q4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607046984?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:50","pubTimestamp":1769781000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA6QMCD5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2606731373","title":"VolitionRx Unveils Study Supporting Nu.Q NETs Blood Test for Hidradenitis Suppurativa Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2606731373","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606731373?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:25","pubTimestamp":1769534702,"startTime":"0","endTime":"0","summary":"VolitionRx Limited has announced the results of a new clinical study demonstrating the use of its Nu.Q NETs assay in patient management for Hidradenitis Suppurativa , a chronic disease affecting approximately 1% of the global population. The Nu.Q NETs assay, which is CE-Marked and commercially available in 27 EU member states, the EEA countries, and the U.K., is designed to detect diseases associated with NETosis. According to the company, the study supports the use of the assay to classify patients with HS and to serve as a surrogate marker for treatment response. The findings have been published and are available in JAMA Dermatology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDLKMbGt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2606878460","title":"Volition Announces Data to Support Use of Nu.q® Nets in New Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2606878460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606878460?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518806,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA15NBNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2606221188","title":"VolitionRX Ltd. Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2606221188","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606221188?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:20","pubTimestamp":1769466053,"startTime":"0","endTime":"0","summary":"VolitionRx Limited will hold a Special Meeting of Stockholders on March 31, 2026, at 93-95 Gloucester Place, London, United Kingdom. The board of directors has circulated proxy materials for the meeting, and all proposals and matters described in the proxy statement will be put forward for shareholder consideration and voting at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL90M5Pg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2605910242","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910242","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605910242?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:57","pubTimestamp":1769000220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2026 07:57 ET (12:57 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2604115480","title":"VolitionRX Expands Nu.Q Vet Cancer Test Access With New Laboratory Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115480","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115480?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:25","pubTimestamp":1768915514,"startTime":"0","endTime":"0","summary":"VolitionRx Limited announced the appointment of two new centralized laboratory providers for its Nu.Q Vet Cancer test in the United States and Asia. Midwest Veterinary Laboratory will offer the Nu.Q Vet Cancer test to customers across all 50 U.S. states starting February 2026. Bioguard, an animal health diagnostics company, will provide the test through its Animal Health Diagnostic Center, which is certified in Taiwan and China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDLn46fg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2603991979","title":"VolitionRX Ltd. Showcases Nu.Q Vet Cancer Test at VMX Veterinary Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603991979","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603991979?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:45","pubTimestamp":1768571113,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. will sponsor an industry symposium at the Veterinary Meeting and Expo  in Orlando, Florida. Dr. Sue Ettinger, also known as \"Dr Sue Cancer Vet,\" will present \"Utilizing the Nu.Q Vet Cancer Test in Practice\" on Monday, January 19 at 2:45pm EST. The Volition Veterinary Diagnostics Development team will also be available at booth 2243 during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL3qj77w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2602373847","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373847?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:15","pubTimestamp":1767960900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 07:15 ET (12:15 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2601292360","title":"BRIEF-Volitionrx Ltd Enters Amended Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601292360","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601292360?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:22","pubTimestamp":1767882155,"startTime":"0","endTime":"0","summary":"BRIEF-Volitionrx Ltd Enters Amended Securities Purchase AgreementJan 8 (Reuters) - VolitionRX Ltd VNRX.A:VOLITIONRX LTD - ENTERS AMENDED SECURITIES PURCHASE AGREEMENTVOLITIONRX LTD - TO RECEIVE $2,000","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y911A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2601606433","title":"VolitionRX Ltd - Enters Amended Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601606433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601606433?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881746,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y911A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2601606173","title":"VolitionRX Ltd - to Receive $2,000,000 From Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2601606173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601606173?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881746,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y911A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2601668360","title":"Press Release: VolitionRx Secures $2.0 Million in Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2601668360","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601668360?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881700,"startTime":"0","endTime":"0","summary":"HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited  , a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement  with Lind Global Asset Management XII LLC , an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Under the Amended Agreement, the Company will receive aggregate gross proceeds of $2,000,000 from the Investor in exchange for the issuance to the Investor of a senior secured convertible promissory note in the principal amount of $2,400,000 , and a five-year common stock purchase warrant to purchase up to 7,000,350 shares of the Company's common stock at an exercise price of $0.5714 per share , subject to the satisfaction of certain closing conditions. As additional consideration to Investor, we have agreed to pay a commitment fee in the amount of $70,000, which shall be paid by deduction from the funding to be received.This press release shall not co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4555","BK4604","VNRX","BK4198","BK4588","BK4585","R","BK4022","TM","BK4232","BK4099"],"gpt_icon":0},{"id":"2601935367","title":"VolitionRX Ltd. unveils corporate deck highlighting cancer and sepsis diagnostics, licensing strategy, and global commercialization plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2601935367","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601935367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:55","pubTimestamp":1767880516,"startTime":"0","endTime":"0","summary":"VolitionRX Ltd. unveils corporate deck highlighting cancer and sepsis diagnostics, licensing strategy, and global commercialization plans. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL62BtzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.volition.com","stockEarnings":[{"period":"1week","weight":0.1463},{"period":"1month","weight":-0.1182},{"period":"3month","weight":-0.2695},{"period":"6month","weight":-0.6594},{"period":"1year","weight":-0.5976},{"period":"ytd","weight":-0.0806}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.113656},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.078292},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.06613},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.026908},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.041011},{"month":6,"riseRate":0.454545,"avgChangeRate":0.012813},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.017569},{"month":8,"riseRate":0.545455,"avgChangeRate":0.012627},{"month":9,"riseRate":0.363636,"avgChangeRate":0.038825},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.008979},{"month":11,"riseRate":0.363636,"avgChangeRate":0.018412},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.037586}],"exchange":"AMEX","name":"VolitionRX","nameEN":"VolitionRX"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VolitionRX,VNRX,VolitionRX股票,VolitionRX股票老虎,VolitionRX股票老虎国际,VolitionRX行情,VolitionRX股票行情,VolitionRX股价,VolitionRX股市,VolitionRX股票价格,VolitionRX股票交易,VolitionRX股票购买,VolitionRX股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}